Incyte Announces Data from Two LIMBER Studies Evaluating Com

Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022

- Phase 2 data demonstrate that the addition of parsaclisib to ruxolitinib (Jakafi®) resulted in spleen volume reduction and improvement in symptom burden in patients with myelofibrosis (MF)

- Initial results of a Phase 1/2 study evaluating the safety and tolerability of INCB00928, an ALK2 inhibitor, show INCB00928 improves anemia in patients with MF both as monotherapy and in combination with ruxolitinib

- These studies are part of our LIMBER program evaluating ruxolitinib combinations and potential new targets for appropriate patients with myeloproliferative neoplasms (MPNs)

Related Keywords

Delaware , United States , American , Mascarenhasj Hemasphere , Peter Langmuir , Abdulraheem Yacoub , Drug Administration , American Society Of Hematology , Exchange Commission , Landmark Survey Available , University Of Kansas Cancer Center , Oncology Drug Development Incyte , Research Foundation , Incyte Corporation , These Phase , American Society , Annual Meeting , New Orleans , Vice President , Oncology Drug Development , Associate Professor , Hematologic Malignancies , Cellular Therapeutics , Kansas Cancer , Full Prescribing Information , Incyte Medical Information , Add On Parsaclisib , Ruxolitinib Therapy , Myelofibrosis Patients With Suboptimal Response , Final Results From , Anemia Due , Accessed February ,

© 2025 Vimarsana